Staging and Treatment Response Evaluation in Malignant Lymphomas – Czech Lymphoma Study Group Recommendations According to Criteria Revised in 2014 (Lugano Classification)

Šýkorová, Alice; Pytlík, Robert; Móciková, Heidi; Belada, David; Benešová, Kateřina; Papajík, Tomáš; Janíková, Andrea; Schwartz, David A.; Procházka, Vít; Vokurka, Samuel; Campr, Vit; Klener, Pavel; Kubáčková, Kateřina; Trněný, Marek

doi:10.14735/amko2016295

Cited by 7 publications

(5 citation statements)

References 41 publications

(83 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Risk stratification was assigned according to international prognostic index (IPI) scores (low risk: 0-1; low-intermediate risk: 2; high-intermediate risk: 3; high risk: 4-5). The responses of treatments were defined according to the International Working Group response criteria (published in 2007) 13 or revised response criteria (published as the Lugano classification, 2014) 14.…”

Section: Methodsmentioning

confidence: 99%

High expression levels of TLR9 and PD-L1 indicates a poor prognosis in patients with angioimmunoblastic T-cell lymphoma: a retrospective study of 88 cases in a single center

Qian¹,

Meng²,

Lv³

et al. 2020

J. Cancer

View full text Add to dashboard Cite

Background: The role of TLR9 expressed by tumor cells in evading immune surveillance was confirmed. PD-L1 expression in tumor cells plays a key role in tumor immune escape, which is associated with poor prognosis. However, the clinical relevance of TLR9 and PD-L1 expression in angioimmunoblastic T-cell lymphoma (AITL) has not been evaluated.Materials and methods: In this study, we identified differentially expressed genes in AITL samples by bioinformatic analysis, and we first examined TLR9 and PD-L1 expression by immunohistochemical staining in patients with AITL and compared these data with clinical features and survival time.Results: It was found that the expression of PD-L1 and multiple TLRs was higher in AITL than normal T-cell samples, and TLR9 and PD-L1 expression displayed complex interactions by bioinformatic analysis. The rates of TLR9 and PD-L1 high expression were 69% and 50%, respectively. High expression of either TLR9 or PD-L1 indicated a poor survival rate for patients with AITL. Multivariate analysis further confirmed that high expression levels of TLR9 and PD-L1 were unfavorable prognostic factors for AITL. We further found inferior overall survival in AITL with clinical features of ECOG status ≥ 2, advanced-stage, elevated serum LDH levels, elevated serum β2-MG levels, and high IPI score.Conclusion: TLR9 and PD-L1 expression may be a novel predictor of prognosis for patients with AITL and may serve as potential therapeutic strategy.

show abstract

Section: Methodsmentioning

confidence: 99%

High expression levels of TLR9 and PD-L1 indicates a poor prognosis in patients with angioimmunoblastic T-cell lymphoma: a retrospective study of 88 cases in a single center

Qian¹,

Meng²,

Lv³

et al. 2020

J. Cancer

View full text Add to dashboard Cite

show abstract

“…The involvement of the spleen and other extranodal sites was determined using diagnostic tools such as CT, enhanced CT, and PET-CT. Treatment response was evaluated according to the 2014 Lugano classification criteria ( 14 ). The response was categorized as complete remission (CR), partial remission (PR), stable disease (SD), or progressive disease (PD).…”

Section: Methodsmentioning

confidence: 99%

Clinicopathologic analysis of nodal T-follicular helper cell lymphomas, a multicenter retrospective study from China

Ma,

Li,

Zuo

et al. 2024

Front. Immunol.

View full text Add to dashboard Cite

BackgroundNodal T-follicular helper cell lymphomas (nTFHLs) represent a new family of peripheral T-cell lymphomas (PTCLs), and comparative studies of their constituents are rare.MethodsThis study retrospectively enrolled 10 patients with nTFHL-F and 30 patients with nTFHL-NOS diagnosed between December 2017 and October 2023 at six large comprehensive tertiary hospitals; 188 patients with nTFHL-AI were diagnosed during the same period at the First Affiliated Hospital of Zhengzhou University for comparison.ResultsCompared with nTFHL-AI, nTFHL-NOS patients exhibited better clinical manifestations, lower TFH expression levels, and a lower Ki-67 index. However, no differences in clinicopathological features were observed between nTFHL-F and nTFHL-AI patients as well as nTFHL-NOS patients. According to the survival analysis, the median OS for patients with nTFHL-NOS, nTFHL-AI, and nTFHL-F were 14.2 months, 10 months, and 5 months, respectively, whereas the median TTP were 14 months, 5 months, and 3 months, respectively. Statistical analysis revealed differences in TTP among the three subtypes(P=0.0173). Among the population of patients receiving CHOP-like induction therapy, there were significant differences in the OS and TTP among the nTFHL-NOS, nTFHL-AI, and nTFHL-F patients (P=0.0134, P=0.0205). Both the GDPT and C-PET regimens significantly improved the ORR, OS, and PFS in nTFHL patients.ConclusionThere are significant differences in the clinical manifestations, pathology, and survival outcomes among the three subtypes of nTFHLs. However, further research with a larger sample size, and involving clinical pathology and molecular genetics is needed to determine the distinctive biological characteristics of these tumors.

show abstract

“…OS was defined as the time interval from the first day of the regimen to death or the final follow‐up. Treatment efficacy was assessed using the revised Cheson Standard Response 15 …”

Section: Methodsmentioning

confidence: 99%

“…Treatment efficacy was assessed using the revised Cheson Standard Response. 15 All AEs were reported from cycle 1, day 1 until 30 days after the last dose of the study drug, regardless of the relationship to treatment. AEs were graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 5.0.…”

Section: Evaluation Criteriamentioning

confidence: 99%

Decitabine combined with RDHAP regimen in relapsed/refractory diffuse large B cell lymphoma

et al. 2023

View full text Add to dashboard Cite

Diffuse large B-cell lymphoma (DLBCL) is the most common subtype of non-Hodgkin lymphoma (NHL), accounting for approximately 30%-40% of cases. The current standard treatment is the R-CHOP regimen, although 30%-40% of patients relapse or develop refractory diseases. 1 Only 13% of these patients undergo high-dose chemotherapy followed by autologous stem cell transplantation (HDT-ASCT). 2 Patients with relapsed/refractory

show abstract

Staging and Treatment Response Evaluation in Malignant Lymphomas – Czech Lymphoma Study Group Recommendations According to Criteria Revised in 2014 (Lugano Classification)

Cited by 7 publications

References 41 publications

High expression levels of TLR9 and PD-L1 indicates a poor prognosis in patients with angioimmunoblastic T-cell lymphoma: a retrospective study of 88 cases in a single center

High expression levels of TLR9 and PD-L1 indicates a poor prognosis in patients with angioimmunoblastic T-cell lymphoma: a retrospective study of 88 cases in a single center

Clinicopathologic analysis of nodal T-follicular helper cell lymphomas, a multicenter retrospective study from China

Decitabine combined with RDHAP regimen in relapsed/refractory diffuse large B cell lymphoma

Contact Info

Product

Resources

About